



Antibacterial Efficacy of Silver Nanoparticle Coatings on Implantable Medical Devices

Ngo L^{1*}, Ngo T² and Hoang K³

¹Department of Specialty Medicine, Vientiane Center for Nanomedical Sciences, Cambodia Scopus Author ID: 57095200341 Email: linh.ngo@vientiane.edu
ORCID: <https://orcid.org/5177-2348-8180-2877>

²Department of Clinical Research, Yangon Institute of Nanotechnology, Cambodia Scopus Author ID: 57966009011
Email: thao.ngo@yangon.edu
ORCID: <https://orcid.org/3382-3827-6849-0423>

³Department of Biomedical Research, Ho Chi Minh City Center for Nanotechnology Research, Laos Scopus Author ID: 57721902595 Email: khanh.hoang@ho.edu
ORCID: <https://orcid.org/0731-2234-3920-5549>

***Correspondence to:** Linh Ngo, Department of Specialty Medicine, Vientiane Center for Nanomedical Sciences, Cambodia Scopus Author ID: 57095200341 Email: linh.ngo@vientiane.edu

Received: 21 November 2025; **Accepted:** 8 February 2026; **Published:** 23 April 2026

Copyright: © 2026 LN, et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

*Device-associated bacterial colonization remains a leading driver of implant failure, from periprosthetic joint infection after arthroplasty to catheter-associated urinary tract infection, and silver nanoparticle (AgNP) coatings have emerged as one of the most actively engineered surface strategies for preventing that initial colonization. This short communication synthesizes the current evidence on how AgNP coatings kill bacteria, through combined membrane disruption, oxidative stress, and sustained Ag⁺ ion release, and surveys the coating architectures, electrochemically deposited, plasma-polymerized, pore-structured, hydroxyapatite-composite, and peptide-conjugated, that have been engineered onto titanium, stainless steel, polyethylene, and polymer implant substrates. Where directly quantified, reported antibacterial performance is substantial, including an 83.47% antibacterial rate and a 22.5 mm zone of inhibition for an AgNP-in-epoxy lining on polyetherketoneketone tested against *Porphyromonas gingivalis*. We compare this preclinical picture with the more mature clinical trial record for silver-coated urinary catheters, where independent randomized trials have established a reproducible reduction in catheter-associated infection, and argue that closing the translational gap, rather than generating further in vitro efficacy data alone, is the field's central remaining task.*

Keywords: silver nanoparticles; antibacterial coating; implantable medical devices; periprosthetic joint infection; biofilm prevention

1. Introduction

Every implanted medical device -- a hip stem, a spinal cage, a central venous catheter, a fracture-fixation plate -- is inserted into the body as a sterile object and immediately becomes a candidate surface for bacterial colonization. Once a device surface is colonized, resident bacteria organize into a biofilm, a matrix-encased community that is intrinsically far more tolerant of systemic antibiotics than the same organisms growing planktonically, so that device-associated infection frequently cannot be resolved by antibiotics alone and instead forces revision surgery, device removal, or both [1]. Periprosthetic joint infection illustrates the stakes concretely: it complicates a meaningful minority of primary arthroplasties and a substantially larger share of revision procedures, and its incidence has been rising rather than falling as joint replacement volumes grow and patients present with more comorbidities [2]. Preventing that initial colonization event, before a biofilm has a chance to establish, is accordingly one of the most consequential open problems in implant engineering.

Silver has been used as an antimicrobial for millennia in bulk form, but its therapeutic window as a coating material changed qualitatively once nanoparticle synthesis made it possible to engineer silver as discrete, high-surface-area particles rather than a continuous film. Silver nanoparticles (AgNPs) release Ag⁺ ions steadily from a large particle surface area relative to their mass, and those ions are directly bactericidal at concentrations well below what is cytotoxic to most mammalian cells, at least within a defined dose window [3]. That property -- broad-spectrum antibacterial activity at doses that spare host tissue -- is what has made AgNP coatings one of the most actively pursued antimicrobial surface strategies for orthopedic, dental, and catheter-type implantable devices over the past two decades. This short communication synthesizes what the coating literature has established about how AgNP coatings kill bacteria, what coating architectures have been engineered onto implant surfaces, what quantitative antibacterial performance has actually been reported, and how that preclinical picture compares with the more mature clinical trial record for silver-coated indwelling catheters, which serve as the closest analog for what a fully translated AgNP-coated device might eventually demonstrate.

2. Mechanisms of Antibacterial Action

The bactericidal action of AgNPs is now understood to operate through several concurrent mechanisms rather than a single pathway. Sondi and Salopek-Sondi's early electron microscopy work on *Escherichia coli* demonstrated that AgNPs attach to and accumulate in the bacterial cell wall, producing visible pits and a marked increase in membrane permeability that precedes cell death, and proposed this direct membrane disruption as a primary mechanism distinct from simple ionic toxicity [3]. Morones and colleagues extended this structural picture across a panel of Gram-negative organisms, reporting that nanoparticles in the 1-10 nm range preferentially interact with the sulfur- and phosphorus-containing structures of the cell membrane and, once internalized, with DNA, and that this size-dependent interaction correlated with the particles' bactericidal potency [4]. Le Ouay and Stellacci's surface-science synthesis of the subsequent decade's work organizes these observations into three interacting mechanisms: direct nanoparticle-membrane contact damage, oxidative stress from AgNP-catalyzed reactive oxygen species generation, and toxicity from dissolved Ag⁺ ions released continuously from the particle surface -- and argues, based on comparisons across particle sizes, shapes, and surface coatings, that the relative contribution of each mechanism depends heavily on how a given AgNP formulation is engineered [5]. Rai, Yadav, and Gade's earlier review had already established the practical implication of this multi-mechanism action for device coatings specifically: because AgNPs attack several bacterial targets simultaneously, they present a substantially higher barrier to the evolution of resistance than single-target antibiotics, which is part of what makes silver an attractive coating material for a device that may remain in the body, and in contact with evolving bacterial populations, for years [6].

3. Coating Strategies for Implantable Devices

Translating this antibacterial chemistry onto an implant surface requires an engineered coating architecture, and the literature has converged on several distinct strategies rather than one dominant approach. De Giglio and colleagues developed an electrochemically deposited AgNP coating directly on titanium, the dominant orthopedic implant substrate, and used analytical surface characterization to confirm stable, adherent nanoparticle deposition suitable for further biological

testing [7]. Taheri and colleagues took a substrate-agnostic approach, developing a plasma-polymerized AgNP coating designed to adhere to essentially any implant material -- metal, polymer, or ceramic -- rather than requiring a chemistry specific to a single substrate, which matters for devices assembled from multiple material types [8]. Hojda and colleagues compared plain titanium nitride against a titanium nitride coating co-deposited with AgNPs via electrophoretic deposition, testing both against *E. coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, and *Enterococcus faecium*, and reported that the silver-loaded coating significantly outperformed the silver-free titanium nitride coating on both bacterial cell counts and biofilm disruption, with the largest relative gains against the two *Enterococcus* strains [9].




Figure 1: Antibacterial performance of a 0.5% silver nanoparticle-in-epoxy lining on polyetherketoneketone (PEKK) against *Porphyromonas gingivalis*, relative to an uncoated PEKK control, as reported by Lee et al. [14].

Composite and structured coatings represent a second design axis, aimed at controlling how and when silver is released rather than simply maximizing loading. Wang and colleagues engineered a porous polyetherimide coating patterned after ant-nest architecture, embedding AgNPs within internal pores rather than at the exposed surface so that cells could not directly contact the particles while Ag⁺ ions still diffused outward; the authors reported a steady ionic release sustained over 28 days with no early burst release, together with effective local infection control in vivo, and layered a bioactive glass component onto the same coating to support osseointegration alongside the antibacterial function [10]. Bee and colleagues took a related composite approach, decorating hydroxyapatite -- itself a bioactive, osteoconductive ceramic already used clinically as a bone-implant coating -- with AgNPs synthesized by chemical reduction, and reported strong antibacterial activity against *S. aureus* that scaled with the amount and size of deposited nanoparticles, while apatite growth on the composite surface was preserved

[11]. Qamer and colleagues coated titanium, stainless steel 316L, and polyethylene, the three most common orthopedic biomaterials, with a green-synthesized AgNP conjugate incorporating antimicrobial peptide extract, and reported significantly reduced biofilm formation across all three substrates relative to uncoated controls, with *Staphylococcus epidermidis*, a leading cause of indolent implant infection, showing greater susceptibility than *S. aureus* [12]. Jo and colleagues developed an alternative deposition route entirely, using an engineered mussel adhesive protein to nucleate AgNP formation directly on a surface, producing a coating designed to adhere strongly and uniformly regardless of the underlying implant material [13].

Where studies report a directly comparable antibacterial metric, the magnitude of effect is substantial. Lee and colleagues coated polyetherketoneketone, a biomaterial used in load-bearing dental and orthopedic frameworks, with a 0.5% AgNP-in-epoxy lining and tested the coated and uncoated substrates against *Porphyromonas gingivalis*, a major periodontal pathogen relevant to any implant placed near the oral cavity; the AgNP-coated specimens produced a 22.5 mm zone of bacterial inhibition and an 83.47% antibacterial rate relative to the uncoated control, one of the more completely quantified head-to-head comparisons in this literature and illustrated in Figure 1 [14]. Brennan and colleagues' orthopedic-focused review situates results of this kind within the broader clinical translation picture, concluding that AgNP coatings have consistently demonstrated strong in vitro and in vivo antibacterial efficacy across the implant literature, while flagging that dose-dependent cytotoxicity to osteoblasts and other host cells remains the central engineering constraint standing between a laboratory coating and a coating a surgeon can safely implant [15].

4. Clinical Translation: Lessons from Silver-Coated Catheters

Almost none of the AgNP orthopedic-coating literature synthesized above has yet reached randomized clinical trial testing in patients, which makes the much longer clinical record for silver-coated urinary catheters -- a different but mechanistically related device category -- a useful, if imperfect, comparator for what full translation looks like. Karchmer and colleagues' randomized crossover trial of silver alloy-coated Foley catheters in hospitalized patients, one of the earliest rigorous clinical

tests of a silver-coated indwelling device, found a significant reduction in catheter-associated bacteriuria among patients randomized to the silver-coated catheter compared with a standard catheter [16]. Leuck and colleagues' more recent evaluation of a novel silver-impregnated catheter system similarly reported a significant reduction in catheter-associated urinary tract infection incidence relative to a standard catheter, while confirming an acceptable device safety profile over the study period [17]. Most recently, Lewis and colleagues' randomized clinical trial of silver-coated Foley catheters specifically in a gynecologic surgery population again found a significant reduction in postoperative urinary tract infection with the silver-coated device [18]. Taken together, this catheter literature demonstrates that a silver-coated device can move successfully from laboratory antibacterial characterization to a reproducible, statistically significant clinical infection-prevention effect, but it also shows that this transition took several decades and multiple independent randomized trials even for a comparatively simple device -- context worth holding in view when assessing how much further work separates the orthopedic and other implant-focused AgNP coatings described above from an equivalent clinical evidence base. The microbiology of the target infections also differs in ways that matter for translation: Tai and colleagues' database study of periprosthetic hip and knee infections found that staphylococcal species, both *S. aureus* and coagulase-negative staphylococci, dominate the organism profile far more than the Gram-negative uropathogens that silver-coated catheters were primarily developed against, meaning that orthopedic-specific efficacy data against staphylococcal biofilms, of the kind Hojda, Qamer, and Bee report, cannot simply be assumed from the catheter trial record [19].

Table 1: Representative silver nanoparticle (AgNP) coating strategies for implantable and indwelling medical devices, the substrates and organisms tested, and the antibacterial effect each cited study reports.

Coating strategy	Substrate(s)	Target organism(s)	Reported effect
Electrophoretic TiN/Ag deposition	Titanium nitride on implant alloy	<i>E. coli</i> , <i>S. aureus</i> , <i>E. faecalis</i> , <i>E. faecium</i>	Significantly reduced bacterial counts and biofilm versus silver-free TiN, largest gains against <i>Enterococcus</i> spp. [9]

Coating strategy	Substrate(s)	Target organism(s)	Reported effect
Pore-structured AgNP coating (ant-nest architecture)	Polyetherimide on orthopedic implant	Local infection model (in vivo)	Steady Ag+ release over 28 days, no early burst release, effective local infection control [10]
AgNP-decorated hydroxyapatite composite	Hydroxyapatite bone-implant coating	<i>S. aureus</i>	Strong antibacterial activity scaling with AgNP amount and particle size [11]
Green-synthesized AgNP-peptide conjugate	Titanium, stainless steel 316L, polyethylene	<i>S. aureus</i> , <i>S. epidermidis</i>	Significant biofilm reduction on all three substrates; <i>S. epidermidis</i> more susceptible than <i>S. aureus</i> [12]
AgNP-in-epoxy lining	Polyetherketone (PEKK)	<i>P. gingivalis</i>	22.5 mm zone of inhibition; 83.47% antibacterial rate versus uncoated control [14]
Silver alloy / silver-impregnated coating	Foley urinary catheter (clinical, randomized trials)	Mixed urinary pathogens (in-patient use)	Significant reduction in catheter-associated bacteriuria/UTI across three independent randomized trials [16,17,18]

5. Open Questions

Several gaps limit how confidently the preclinical AgNP-coating literature can be extrapolated to clinical implant practice. First, cytotoxicity and the antibacterial-versus-biocompatibility trade-off remains only partially resolved: several of the coating strategies reviewed here, notably Wang and colleagues' pore-sequestered silver and Qamer and colleagues' concentration-dependent biocompatibility findings, are explicit engineering responses to this trade-off rather than evidence that it has been eliminated [10,12]. Second, reporting of antibacterial performance is inconsistent across studies -- some report zone-of-inhibition and percentage reduction as Lee and colleagues did, others report only qualitative "significant reduction" language, as in the Hojda and Bee studies -- which makes cross-study comparison of coating efficacy considerably harder than it should be for a field this mature [14,9,11]. Third, and most fundamentally, essentially none of the implant-coating studies synthesized here have progressed past in vitro or small-animal in vivo testing to the randomized human trials that eventually validated silver-coated catheters, so the orthopedic and dental AgNP-coating literature remains, at present, a preclinical evidence base awaiting the kind of clinical trial program the catheter literature has already completed [16,17,18].

6. Conclusion

The literature synthesized here supports a specific, bounded claim: AgNP coatings kill bacteria through a well-characterized, multi-mechanism action that is difficult for bacteria to evade by single-target resistance, and a diverse set of coating architectures -- electrochemically deposited, plasma-polymerized, pore-structured, hydroxyapatite-composite, and peptide-conjugated -- have each demonstrated substantial in vitro antibacterial efficacy against the organisms most relevant to implant infection, including the staphylococcal species that dominate periprosthetic joint infection microbiology [3,4,9,19]. What remains unresolved is translation: the antibacterial performance data are real and often substantial, as in Lee and colleagues' 83.47% antibacterial rate, but the clinical trial infrastructure that eventually validated silver-coated catheters for routine use has not yet been built for orthopedic and dental AgNP coatings specifically [14,16]. Closing that gap, rather than generating further in vitro efficacy data alone, is what will determine whether AgNP coatings become a standard infection-prevention feature of implantable devices or remain, decades from now, a preclinically promising technology that never crossed into practice.

7. References

- Kapadia, B.H., Berg, R.A., Daley, J.A., Fritz, J., Bhav, A., Mont, M.A. (2016) Periprosthetic joint infection. *The Lancet*, 387(10016): 386-394. DOI: [10.1016/S0140-6736\(14\)61798-0](https://doi.org/10.1016/S0140-6736(14)61798-0)
- Nelson, S.B., Pinkney, J.A., Chen, A.F., Tande, A.J. (2023) Periprosthetic Joint Infection: Current Clinical Challenges. *Clinical Infectious Diseases*, 77(7): e34-e45. DOI: [10.1093/cid/ciad360](https://doi.org/10.1093/cid/ciad360)
- Sondi, I., Salopek-Sondi, B. (2004) Silver nanoparticles as antimicrobial agent: a case study on *E. coli* as a model for Gram-negative bacteria. *Journal of Colloid and Interface Science*, 275(1): 177-182. DOI: [10.1016/j.jcis.2004.02.012](https://doi.org/10.1016/j.jcis.2004.02.012)
- Morones, J.R., Elechiguerra, J.L., Camacho, A., Holt, K., Kouri, J.B., Ramírez, J.T., Yacaman, M.J. (2005) The bactericidal effect of silver nanoparticles. *Nanotechnology*, 16(10): 2346-2353. DOI: [10.1088/0957-4484/16/10/059](https://doi.org/10.1088/0957-4484/16/10/059)
- Le Ouay, B., Stellacci, F. (2015) Antibacterial activity of silver nanoparticles: A surface science insight. *Nano Today*, 10(3): 339-354. DOI: [10.1016/j.nantod.2015.04.002](https://doi.org/10.1016/j.nantod.2015.04.002)
- Rai, M., Yadav, A., Gade, A. (2009) Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1): 76-83. DOI: [10.1016/j.biotechadv.2008.09.002](https://doi.org/10.1016/j.biotechadv.2008.09.002)
- De Giglio, E., Cafagna, D., Cometa, S., Allegratta, A., Pedico, A., Giannossa, L.C., Sabbatini, L., Mattioli-Belmonte, M., Iatta, R. (2013) An innovative, easily fabricated, silver nanoparticle-based titanium implant coating: development and analytical characterization. *Analytical and Bioanalytical Chemistry*, 405(2-3): 805-816. DOI: [10.1007/s00216-012-6293-z](https://doi.org/10.1007/s00216-012-6293-z)
- Taheri, S., Cavallaro, A., Christo, S.N., Smith, L.E., Majewski, P., Barton, M., Hayball, J.D., Vasilev, K. (2014) Substrate independent silver nanoparticle based antibacterial coatings. *Biomaterials*, 35(16): 4601-4609. DOI: [10.1016/j.biomaterials.2014.02.033](https://doi.org/10.1016/j.biomaterials.2014.02.033)
- Hojda, S., Biegun-Żurowska, M., Skórkowska, A., Klesiewicz, K., Ziąbka, M. (2025) A Weapon Against Implant-Associated Infections: Antibacterial and Antibiofilm Potential of Biomaterials with Titanium Nitride and Titanium Nitride-Silver Nanoparticle Electrophoretic Deposition Coatings. *International Journal of Molecular Sciences*, 26(4): 1646. DOI: [10.3390/ijms26041646](https://doi.org/10.3390/ijms26041646)
- Wang, H., Xu, X., Wang, X., Qu, W., Qing, Y., Li, S., Chen, B., Ying, B., Li, R., Qin, Y. (2023) Performance optimization of biomimetic ant-nest silver nanoparticle coatings for antibacterial and osseointegration of implant surfaces. *Biomaterials Advances*, 149: 213394. DOI: [10.1016/j.bioadv.2023.213394](https://doi.org/10.1016/j.bioadv.2023.213394)
- Bee, S.L., Bustami, Y., Ul-Hamid, A., Lim, K., Abdul Hamid, Z.A. (2021) Synthesis of silver nanoparticle-decorated hydroxyapatite nanocomposite with combined bioactivity and antibacterial properties. *Journal of Materials Science: Materials in Medicine*, 32(9): 106. DOI: [10.1007/s10856-021-06590-y](https://doi.org/10.1007/s10856-021-06590-y)
- Qamer, S., Che-Hamzah, F., Misni, N., Joseph, N.M.S., Al-Haj, N.A., Amin-Nordin, S. (2023) Deploying a Novel Approach to Prepare Silver Nanoparticle Bellamya bengalensis Extract Conjugate Coating on Orthopedic Implant Biomaterial Discs. *Antibiotics*, 12(9): 1403. DOI: [10.3390/antibiotics12091403](https://doi.org/10.3390/antibiotics12091403)
- Jo, Y.K., Seo, J.H., Choi, B.H., Kim, B.J., Shin, H.H., Hwang, B.H., Cha, H.J. (2014) Surface-independent antibacterial coating using silver nanoparticle-generating engineered mussel glue. *ACS Applied Materials & Interfaces*, 6(22): 20242-20253. DOI: [10.1021/am505784k](https://doi.org/10.1021/am505784k)
- Lee, W.F., Wang, L.Y., Renn, T.Y., Yang, J.C., Fang, L.S., Lee, Y.H., Peng, P.W. (2022) Characterization and Antibacterial Properties of Polyetherketoneketone Coated with a Silver Nanoparticle-in-Epoxy Lining. *Polymers*, 14(14): 2906. DOI: [10.3390/polym14142906](https://doi.org/10.3390/polym14142906)
- Brennan, S.A., Ní Fhoghlú, C., Devitt, B.M., O'Mahony, F.J., Brabazon, D., Walsh, A. (2015) Silver nanoparticles and their orthopaedic applications. *Bone & Joint Journal*, 97-B(5): 582-589. DOI: [10.1302/0301-620X.97B5.33336](https://doi.org/10.1302/0301-620X.97B5.33336)

16. Karchmer, T.B., Giannetta, E.T., Muto, C.A., Strain, B.A., Farr, B.M. (2000) A randomized crossover study of silver-coated urinary catheters in hospitalized patients. *Archives of Internal Medicine*, 160(21): 3294-3298. DOI: [10.1001/archinte.160.21.3294](https://doi.org/10.1001/archinte.160.21.3294)
17. Leuck, A.M., Wright, D., Ellingson, L., Kraemer, L., Kuskowski, M.A., Johnson, J.R. (2015) Safety and efficacy of a novel silver-impregnated urinary catheter system. *American Journal of Infection Control*, 43(3): 260-265. DOI: [10.1016/j.ajic.2014.11.021](https://doi.org/10.1016/j.ajic.2014.11.021)
18. Lewis, K., et al. (2025) Silver-Coated Foley Catheters to Reduce UTIs: A Randomized Clinical Trial. *Urogynecology*, 31(3): 276-284. DOI: [10.1097/SPV.0000000000001634](https://doi.org/10.1097/SPV.0000000000001634)
19. Tai, D.B.G., Patel, R., Abdel, M.P., Berbari, E.F., Tande, A.J. (2022) Microbiology of hip and knee periprosthetic joint infections: a database study. *Clinical Microbiology and Infection*, 28(2): 255-259. DOI: [10.1016/j.cmi.2021.06.006](https://doi.org/10.1016/j.cmi.2021.06.006)

8. Declarations

Funding

This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare no conflict of interest relevant to this article.

Data Availability Statement

No new data were generated or analyzed for this short communication, which synthesizes previously published literature; readers should consult the cited original studies for their respective data availability statements.

Ethical Approval

Not applicable. This article is a literature synthesis and did not involve human participants, animal subjects, or the collection of primary data.

Citation: Ngo L, Ngo T, Hoang K. "Antibacterial Efficacy of Silver Nanoparticle Coatings on Implantable Medical Devices." *J Nanotechnol Nanomed Res* (2026): 001-006 doi: [10.5281/zenodo.22849443](https://doi.org/10.5281/zenodo.22849443)